Arix Bioscience plc announces the outcome of its Strategic Implementation Review (the "Review") together with a number of immediate Board changes. The Company's Executive Chairman, Naseem Amin, has left the Company with immediate effect. Furthermore, the Company has confirmed the Board appointments of: Peregrine Moncreiffe, who joins as non-executive Chairman and is considered by the Board to be independent on appointment for the purposes of the UK Corporate Governance Code; and Maureen O'Connell and Isaac Kohlberg as non-executive directors nominated by the Company's largest shareholder, Acacia Research Corporation, and therefore not deemed to be independent directors on appointment for the purposes of the UK Corporate Governance Code. In light of these changes, Professor Trevor Jones CBE, FMedSci, has decided not to seek re-election at the coming Annual General Meeting ("AGM"), having joined the Board prior to the Company's IPO in 2017. Axel Wieandt and James Noble will no longer be joining the Board.